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Abstract
The core protein of hepatitis B virus encompasses B- and T-cell immunodominant epitopes and
subdivided into two domains: the N-terminal and the functional C-terminal consisted
phosphorylation sites. Mutations of the core gene may change the conformation of the core protein
or cause alteration of important epitopes in the host immune response. In this study twenty nine
men (mean age 40 ± 9 years old) with chronic hepatitis B were recruited for direct sequencing of
the core gene. Serum ALT and HBV DNA level were measured at the time of liver biopsy. The
effects of core protein mutations on patients' characteristics and subsequently mutations in B cell,
T helper and cytotoxic T lymphocyte (CTL) epitopes and also C-terminal domain of core protein
on the activity of liver disease was evaluated. Liver fibrosis was significantly increased in patients
with core protein mutation (1.0 ± 0.8 vs 1.9 ± 1.4 for mean stage of fibrosis P = 0.05). Mutations
in CTL epitopes and in phosphorylation sites of C-terminal domain of core protein also were
associated with higher liver fibrosis (P = 0.003 and P = 0.04; Fisher's exact test for both). Patients
with mutation in C-terminal domain had higher serum ALT (62 ± 17 vs 36 ± 12 IU/l, p = 0.02).
Patients with mutations in B cell and T helper epitopes did not show significant difference in the
clinical features. Our data suggests that core protein mutations in CTL epitopes and C-terminal
domain accompanied with higher stage of liver fibrosis may be due to alterations in the function of
core protein.
Introduction
Worldwide, the 350 million people with chronic hepatitis
B have a 15-25% risk of dying from HBV-related liver dis-
eases, including cirrhosis and hepatocellular carcinoma
[1]. It is evident that 70-84% of cirrhotic patients and 72%
of individuals with hepatocellular carcinoma in Iran have
evidence of exposure to HBV [2].
Naturally occurring mutations of hepatitis B virus (HBV)
genome have an important role in the activity of HBV
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related liver diseases. Patients with long standing active
liver disease are at high risk to develop liver cirrhosis or
hepatocellular carcinoma [3]. The genome of hepatitis B
virus encodes four overlapping open reading frames that
are translated to viral core protein or HBc particle, the sur-
face proteins, a reverse transcriptase (RT), and HBx [4].
The core protein is the major polypeptide of the nucleo-
capsid that during virus assembly polymerizes around a
complex consisting of pregenomic mRNA and viral
polymerase [5]. Core protein with genotype D which is
frequent in Iran [6] holding 183 amino acids with a set of
closely linked α-helices [7] and consists of two distinct
domains, an N-terminal domain with 144 residues
required for the assembly of the 32 nm nucleocapsid and
a functional C-terminal domain [5,8]. Empty core shells
made from truncated HBc at residue 149 revealed the
important role of C-terminal in viral genome binding and
nuclear transport of the core protein [9-11]. The C-termi-
nal arginine-rich domain with a high similarity to pro-
tamin, consists of three repeated SPRRR motifs
corresponded to the part of core protein that interact
closely with RNA [5]. In this domain phosphorylated site
residues located in amino acid sequences 155-183. Imma-
ture nucleocapsids which contain RNA are phosphor-
ylated at six sites, while the mature nucleocapsids which
contain DNA are completely dephosphorylated either
inside cells or in extracellular virions [9]. This phosphor-
ylation clearly plays an important role in the regulation of
the function of C-terminal core protein [10,12]. Regard to
HBc particles include into the HBV vaccines it can be dem-
onstrated that core protein is a major target for antiviral
immune response [13]. There is evidence that the HBc
represents an important target for immune mediated viral
clearance [14] by inducing B cell, T helper cell and cyto-
toxic T lymphocyte (CTL) responses [15]. Important rec-
ognition sites of the core protein are represented by the
amino acid sequences 18-27, 88-96 and 141-151 for the
CTL epitopes and amino acid sequences 1-20, 28-47, 50-
69, 72-105 and 108-165 for T helper epitopes [15-17].
The immunodominant B cell recognition sites within
HBcAg have been found around residues 74-89 and 126-
135 [15,16]. Mutations in both B- and T-cell epitopes
associated with viral persistence[16,18] influencing the
host immune response and also the natural course of
infection [19]. Previous studies showed that mutations in
the region of the CTL epitopes promoted the immune
selection pressure accompanied with particular clinical
manifestations [20,21]. The Inflammatory activity pro-
duced by viral adaptive mechanism may persist in up to
15% of cases, leading to the development of cirrhosis
[22].
Mutations in the functional C-terminal domain of the
core protein might impact on other biochemical proper-
ties of this protein that have not been studied well. Con-
sidering the importance of the C-terminal core protein
during viral replication that might be in interaction with
some cellular proteins, our study objectives were to pro-
vide a pilot data in a group of male patients with chronic
hepatitis B for the presence of mutations in the C-terminal
of the core protein as well as in B cell, T helper and CTL
epitopes of HBV core gene sequence and the effects of
these mutations on the clinical, biochemical and virolog-
ical parameters of patients. We also employed a computa-
tional prediction approach to define the function of the
core protein.
Materials and methods
Human Subjects and Clinical Assessment
Chronic hepatitis B patients with HBeAg negative attend-
ing the Hepatitis Clinic of Shariati Hospital were evalu-
ated. Twenty nine male subjects with detectable HBV
DNA and candidate for liver biopsy were enrolled for the
analysis of the prevalence of HBc mutations. The assessed
laboratory parameters were included serum alanine ami-
notransferase (ALT) and viral load measured by standard
methods. Serological markers for HBsAg, HBeAg were
tested using commercially available enzyme-linked
immunosorbent assay kits from RADIM (Italy). Liver
biopsies from all patients were performed to define the
stage of fibrosis using the modified HAI scoring system
[23]. Serum samples were collected at the initial assess-
ment before liver biopsy. Concurrence of hepatitis C virus
and human immunodeficiency virus infections and
autoimmune liver disease was excluded for all enrolled
individuals. None of the patients received antiviral treat-
ment prior to liver biopsy. Study protocol was approved
by the Ethics Committee of our unit.
Quantitative HBV DNA Assay and Direct Sequencing of 
Core Protein
HBV DNA was extracted from 200 μl of serum using
QIAamp DNA Blood Mini Kit (QIAGEN USA). HBV DNA
was then quantified in the Light-Cycler (Roche) using the
RealART™ HBV LC PCR (QIAGEN, Hilden, Germany)
according to the manufacturer's instructions. To amplify
the nucleotide sequence encoding HBcAg, a pair of prim-
ers designed for PCR, the forward primer (position 374-
392): 5'-TAGGAGGCTGTAGGCATAA-3' and the reverse
primer (Position 1095-1114): 5'-GAACAGTAGAA-
GAATAAAGC-3'. Sequences were obtained by direct
sequencing of a fresh PCR product on an ABI automated
sequencer following concentration using a QIAEX II pro-
tocol (Qiagen, Crawley, UK).
Analysis of Core Protein by Bioinformatics Tools
Deduced amino acid sequences of 29 core genes were
aligned using CLUSTALX developed by the National
Center for Biotechnology Information (NCBI, Bethesda,
MD). Sequence similarity was assessed using BLASTPVirology Journal 2009, 6:209 http://www.virologyj.com/content/6/1/209
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(NCBI, Bethesda, MD) with searching protein sequence
databases. The nature of the kinase to interact with core
protein was predicted by NetPhosK as a kinase-specific
phosphorylation site predictor (online at http://
www.cbs.dtu.dk/services/NetPhosK/). The biological
function process of core protein was predicted by Protein
Function Prediction (PFP) Version 2.0 beta release
(online at http://dragon.bio.purdue.edu/pfp).
Statistical Analysis
Continuous variables were compared using an independ-
ent t-test and categorical variables were compared using
Fisher's exact test. The data are expressed as the mean ±
SD. SPSS for Windows Version 14 (SPSS Inc, Chicago,
USA) was used for all analyses. Two-tailed P value of <
0.05 was considered to be statistically significant.
Results
Clinical, Laboratory, and Virological Data of the Patients
The study group included 29 male subjects with a mean of
42 ± 9 years old. All patients had liver biopsies with the
average length of 1.6 ± 0.8 cm and portal triads numbered
9 ± 6 per biopsy. HAI score and stage of fibrosis had a
mean of 5.7 ± 2.4 and 1.6 ± 1.3 respectively (Table 1).
Deduced amino acid sequences encoding the core protein
of HBV from 29 patients against HBV genotype D consen-
sus sequence showed that all patients were infected with
genotype D. Nineteen of 29 (65.5%) patients had amino
acid mutations in the full length of core protein while
mutations in the phosphorylation site of the C-terminal
were detected in 5 (17.5%). Amino acid residues 77, 80,
130 and 135 corresponded to B cell epitopes, amino acid
residues 12, 35, 38, 64, 66, 113 and 116 to T helper
epitopes and amino acid residues 93, 147 and 151
restricted to CTL epitopes [15,20]. Positions of mutations
in deduced amino acid residues compared to consensus
residue of genotype D in 29 patients are shown in Table 2.
Association of Core Protein Mutations with the Outcome 
of HBV Infection
Comparisons of various clinical features in terms of the
presence of mutations in the core protein are presented in
Table 1. The presence of mutations in core protein was
associated with higher serum ALT although this was not
significant. However liver fibrosis significantly increase in
patients with core protein mutation (1.0 ± 0.8 vs 1.9 ± 1.4
P = 0.05). When the Immunodominant epitopes and C-
terminal domain of HBV core protein were separately ana-
lyzed the mutation of CTL epitopes showed higher viral
replication (4.1 ± 0.8 vs 4.9 ± 0.7 log copies/ml, p = 0.05).
There was no significant difference in the clinical features
of patients with mutation in B cell and T helper epitopes.
We observed a significantly increased serum ALT of
patients with mutations in C-terminal domain (36 ± 12 vs
62 ± 17 IU/I, P = 0.02). Table 3 presented the clinical find-
ings of chronic hepatitis B patients in correlation with
mutations in Immunodominant epitopes and C-terminal
domain of HBV core protein. The mean of HAI score and
fibrosis stage in subjects with mutations in C-terminal
domain when compared with those without this muta-
tions were 7.6 ± 2.2 vs 5.3 ± 2.2, p = 0.06 and 3.4 ± 1.1 vs
1.3 ± 0.7, p = 0.02. However, we found no significant dif-
ference between the mean score of HAI and fibrosis stage
with mutations in CTL epitopes.
To examine the relationship of these mutations with the
stage of fibrosis, patients were classified based on the
score of liver fibrosis less and more than 2 (set as cut off
point). As illustrated in Table 4, statistical analysis of the
relationships between the mutations in the core gene and
the stage of fibrosis showed that mutations in C-terminal
domain with codon 181 being most frequently affected
were significantly associated with development of liver
fibrosis. Mutations in CTL epitopes of core protein also
associated with higher liver fibrosis (P = 0.003 and P =
0.04; Fisher's exact test for both).
Table 1: Analysis of clinical factors in relation to the presence of mutations in the core protein in 29 patients with chronic hepatitis B virus infection
Clinical factor All patients (n = 29) Wild Type
(n = 10)
Mutant
(n = 19)
P value
Age* (Years) 42 ± 9 43 ± 8 41 ± 9 0.5
ALT* (IU/l) 41 ± 16 34 ± 13 44 ± 16 0.09
HBV DNA*
(Log copies/ml)
4.2 ± 0.8 4.0 ± 0.9 4.3 ± 0.8 0.4
HAI score* 5.7 ± 2.4 5.1 ± 2.2 6.1 ± 2.4 0.2
Stage of Fibrosis* 1.6 ± 1.3 1.0 ± 0.8 1.9 ± 1.4 0.05
*Mean ± SDVirology Journal 2009, 6:209 http://www.virologyj.com/content/6/1/209
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Table 2: Amino Acid mutation of HBc sequence deviated from HBV core gene. 
T helper epitopes CTL epitopes B cell epitopes C-terminal
subject T12 S35 Y38 E64 M66 E113 I116 M93 T147 R151 E77 A80 P130 P135 S176 S181
1 - -- - --- - --- - --- -
2 - -- DI-- - --- - --- P
3 - -- - --- - --- - --- -
4 --F - --- - --Q- --- -
5 S - - - --- - --- - -V A -
6 - -- - --- - ---T--- -
7 - -- - --- - --- - --- -
8 - -- - ---V---V--- -
9 - -- D--- - --- - --- P
10 - -- - --- - --- - --- -
11 - -- - ---T---V--- -
12 - T- - --- - --- - --- -
13 - -- - --- - --- - --- -
14 - -- - --- - --- - --- -
15 - -- - --- - --- - --- -
16 - -- - --- - --- -Q -- -
17 - -- D--- - --- - --- -
18 - -- - --- - --- - --- -
19 - -F - --- - --- - --- P
20 - -- - --L - --- - --- -
21 - -- - --- - --- - --- -
22 -- - D--- - --- - -Q- -
23 S- - - I - - - - - - - Q- - -
24 - -- - --- - --- - --- -
25 --F - --- - -R- - --- P
26 - -- - - Q - - --- - --- -
27 - -- - ---T---V--- -Virology Journal 2009, 6:209 http://www.virologyj.com/content/6/1/209
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Functional Analysis of Core Protein
Core protein with the largest number of serine sites in C-
terminal tail could be widely phosphorylated by kinases.
Amino acid residues 176 and 181 which were defined as
mutation sites in current study had high score perform-
ance value for different kinases presented by NetPhosK
predictor. PFP algorithm searched conventional databases
with relative probability of Gene Ontologies (GO) to pre-
dict the most probable GO annotations in three Biological
Process (BP), Molecular Function (MF) and Cellular Com-
ponent (CC) categories which is presented in Fig. 1 and
Table 5. According to this prediction the feature of viral
nucleocapsid with the highest score of 73709 in CC cate-
gory related to the full length of core protein while the
function of core protein in two other categories BP and
MF limited to C-terminal domain.
Discussion
Mutant HBV could display enhanced virulence with
increased levels of HBV replication, or alteration of
epitopes which is important in the host immune
response. Sequence variation in core protein is one of the
powerful viral strategies for escaping recognition by the
host's immune response linked to virus persistence or
severity of chronic hepatitis B infection [18]. The reason
for selection of amino acid changes in hepatitis B virus
proteins, as well as their functional or immunological rel-
evance is speculative [24]. Through the evolution, most
functional DNA is expected to have attained a sequence
that is near optimal for its environment [25]. Previous
work from Iran has indicated a high nucleotide identity
for HBV isolates from 98.4 to 100% [6] in overall that sug-
gests mutations in the HBV core gene sequence were more
likely resulted from natural selection during the course of
infection.
We detected mutations in immunedominant epitopes
and C-terminal domain of core protein in 65.5% of our
patients with chronic hepatitis B. The results revealed
increased liver fibrosis in patients with mutation in both
C-terminal domain and CTL epitopes. The mean of
fibrotic stage found to be highest in patients with muta-
tions in phosphorylation sites of C-terminal domain.
Patients with mutations in the CTL epitopes accompanied
with active viral replication. A proposed mechanism for
this observation is that selection of mutations in the CTL
epitopes alters core antigenicity that results in not to be
recognized by the corresponding immune response and
consequently induce a new immune response as evi-
denced by the high levels of HBV DNA recorded in such
28 - T- D--- - --- - --- -
29 - -- - --- -C-- - --- -
Frequency 
(%)
2(6.9) 2(6.9) 3(10.3) 5(17.2) 2(6.9) 1(3.4) 1(3.4) 3(10.3) 1(3.4) 1(3.4) 1(3.4) 4(13.8) 2(6.9) 2(6.9) 1(3.4) 4(13.8)
The consensus sequence of genotype D is shown in the first line. Dashes represent residues identical to the reference residues.
Table 2: Amino Acid mutation of HBc sequence deviated from HBV core gene.  (Continued)
Table 3: The correlation of mutations in Immunodominant epitopes and C-terminal domain of HBV core protein with clinical finding of 29 chronic 
hepatitis B patients
Immunodominant epitopes
Wild type/Mutant**
Wild type/Mutant**
Mutation site B cell P* CTL P* T helper P* C-terminal domain P*
Frequency (%) 20/9 (68/32) 24/5 (82/17) 16/13 (55/45) 24/5 (82/17)
Age (Years) 42 ± 8/40 ± 9.6 0.5 42 ± 8.3/38 ± 9.3 0.3 42 ± 8.7/41 ± 8.5 0.5 41 ± 8/44 ± 10 0.6
ALT (IU/l) 42 ± 18/38 ± 11 0.4 39 ± 14/48 ± 21 0.4 35 ± 13/47 ± 17 0.06 36 ± 12/62 ± 17 0.02
HBV DNA
(Log copies/ml)
4.2 ± 0.7/4.2 ± 1 0.9 4.1 ± 0.8/4.9 ± 0.7 0.05 4.3 ± 0.9/4.2 ± 0.7 0.6 4.2 ± 0.9/4.5 ± 0.3 0.2
HAI score 6 ± 2.4/5.2 ± 2.4 0.4 5.4 ± 2.3/7.4 ± 2.1 0.1 5.6 ± 2/5.8 ± 2.8 0.6 5.3 ± 2.2/7.6 ± 2.2 0.06
Stage of Fibrosis 1.7 ± 1.3/1.4 ± 1 0.4 1.3 ± 1/2.8 ± 1.4 0.3 1.3 ± 0.9/1.9 ± 1.5 0.2 1.3 ± 0.7/3.4 ± 1.1 0.02
*t Test. **Mean ± SDVirology Journal 2009, 6:209 http://www.virologyj.com/content/6/1/209
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Table 4: The relationships between the mutations in the core gene and the Stage of fibrosis
Core region Stage of Fibrosis Patients with mutation in core protein
(n = 19)
Mutations in: Mean ± SD Fibrosis score <2(%) Fibrosis score >2 (%) P-value*
Core protein 1.9 ± 1.3 13(68) 6(32) 0.06
T helper epitopes 1.9 ± 1.5 9(69) 4(31) 0.3
CTL epitopes 2.8 ± 1.4 2(40) 3(60) 0.04
B cell epitopes 1.4 ± 1.1 7(77) 2(23) 1.0
C-terminal domain 3.4 ± 1.1 1(20) 4(80) 0.003
*Fisher's exact test P-value
#Number (%)
predicted GO annotations for HBV core protein sequence, The PFP algorithm scored GO terms individually and includes  information from distantly related sequences to HBV core protein Figure 1
predicted GO annotations for HBV core protein sequence, The PFP algorithm scored GO terms individually 
and includes information from distantly related sequences to HBV core protein. The function of each GO has been 
shown in table 5.Virology Journal 2009, 6:209 http://www.virologyj.com/content/6/1/209
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cases. Patients with mutation in C-terminal domain of
core protein had higher level of ALT than their counter-
parts. Elevated aminotransferase values reflect increased
histologic necroinflammatory disease activity.
The structure of core protein is largely α-helical rods with
C-terminal basic tail that interact closely with viral RNA
pregenome or the viral DNA genome [11]. The C-terminal
of the core protein is highly conserved with repetitive
structure that is required for many aspects of viral produc-
tion. This may be due to its functional significance, as well
as to the overlapping P gene [8,10]. HBV core protein
appears as a phosphoprotein and many kinases have been
reported to be associated with viral capsid [26]. This was
confirmed by NetPhosK predictor tool in which C-termi-
nal of core protein is phosphorylated by multiple protein
kinases to interact with intracellular protein. Phosphor-
ylation is the most important and best understood modi-
fication to modulate protein activity and signal
propagation for homeostasis processes like cell cycle pro-
gression, differentiation, development and peptide hor-
mone response [27]. The maturation stage of the HBV has
been shown to be correlated to the phosphorylation state
of core molecules [12]. This phosphorylation clearly plays
an important role in the regulation of C-terminal domain
function [28].
To explain the effect of mutations of core protein in the
biological process of the cell, we predicted the major func-
tions of the core protein of hepatitis B virus. Protein pre-
diction function showed that viral nucleocapsid activity
has the highest score for the whole of HBc molecule in cel-
lular component GO category (Fig. 1). This is consistent
with experimental data that the HBc sequence 1-144 was
sufficient for self assembly and HBV pregenome encapsi-
dation but not for binding to the viral pregenome or the
viral DNA genome and the production of relaxed circular
HBV DNA [5,10].
Furthermore, other predicted functions of HBc were lim-
ited to C-terminal domain which is rich in phosphoryla-
tion sites (Fig. 1). We suggested that the molecular
function and biological process of core protein are more
affected by mutations mainly in phosphrylation sites of C-
Table 5: Prediction scores for top 5 predictions function of HBV core protein in each GO category
GO term Short Def Raw Score Term Type
GO0030154 cell differentiation 13589.15 BP
GO0007399 neurogenesis 11229.85 BP
GO0042981 regulation of apoptosis 9909.73 BP
GO0006916 anti-apoptosis 5241.9 BP
GO0006633 fatty acid biosynthesis 4198.2 BP
GO0003723 RNA binding 11434.09 MF
GO0005083 small GTPase regulatory/interacting protein activity 4155.72 MF
GO0000166 nucleotide binding 3985.78 MF
GO0046872 metal ion binding 3868.07 MF
GO0008987 quinolinate synthetase A activity 3672.6 MF
GO0019013 viral nucleocapsid 73709.99 CC
GO0009507 chloroplast 6016.97 CC
GO0005739 mitochondrion 3530.83 CC
GO0016021 integral to membrane 3426.14 CC
GO0016528 sarcoplasm 2591.69 CCVirology Journal 2009, 6:209 http://www.virologyj.com/content/6/1/209
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terminal domain. Usuda et al showed that HBV core pro-
teins (p21c) from symptom-free carriers have a higher
extent of phosphorylation than hepatitis patients [29]
which is consistent with our finding in this study. In this
study, 4 out of 5 mutations in the phosphorylation sites
of the C-terminal core protein related to a proline replac-
ing a serine residue at position 181 that is particularly fre-
quent in HBV of patients with hepatocellular carcinoma
or end stage liver disease [30,31]. It was demonstrated by
Kim et al, that the intracellular level of HBx can be down-
regulated by HBc via a novel mechanism involving the
activation of the proteasome-mediated degradation of
HBx. They showed that the C-terminal half of HBc is
responsible for its inhibitory effect and suggested that HBc
act as a novel regulator of the HBV life cycle and hepato-
cellular carcinogenesis [32]. Mutation of phosphorylation
sites in the C-terminal domain might change the regula-
tory effects of HBc on HBx and consequensing HBx-medi-
ated apoptosis that could be interpreted by predicted
apoptotic regulatory function of HBc. Some unknown sec-
ondary structure as a result of mutation in the core protein
may determine its role in the biological function and rep-
lication of hepadnavirus. Additional in vivo studies for
the effects of core protein mutations on cellular function
are required to determine its precise impact on the devel-
opment of liver fibrosis. These findings may provide use-
ful insights for the design of improved drug for the
treatment of HBV infection.
Conclusion
In conclusion, HBV populations with combinations of
mutations in phosphorylation site in C-terminal domain
and CTL epitopes of core protein were associated with
more severe liver fibrosis.
Abbreviations used in this paper
(HBV): Hepatitis B virus; (CHB): Chronic hepatitis B;
(CTL): Cytotoxic T lymphocyte.
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